KANUMA (sebelipase alfa) injection is used for the treatment of patients with lysosomal acid lipase deficiency

KANUMA™ is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency

KANUMA (sebelipase alfa) injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KANUMA (sebelipase alfa) injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KANUMA (sebelipase alfa) injection medicine cost price in India.

The order for KANUMA (sebelipase alfa) injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Sebelipase alfa is used to treat lysosomal acid lipase deficiency. This is a life-threatening genetic disorder that can damage major organs in the body and lead to early death. Sebelipase alfa replaces the missing enzyme when the body does not have enough of its own.

KANUMA (sebelipase alfa) injection, for intravenous use Initial U.S. Approval: 2015

Generic Name: sebelipase alfa

Injection: 20 mg/10 mL (2 mg/mL) solution in single-use vials.

Kanuma Injection (sebelipase alfa)

KANUMA (sebelipase alfa) injection is available.

Get In Touch

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

KANUMA (sebelipase alfa) injection suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KANUMA (sebelipase alfa) injection on prescription and Import License in Patient's Name only.

For overseas patients, KANUMA (sebelipase alfa) injection can be made available in Send your enquiry to find KANUMA (sebelipase alfa) injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for KANUMA (sebelipase alfa) injection.

For KANUMA (sebelipase alfa) injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

ADDING MULTIMEDIA FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) For More Details

European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D) For More Details